Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04577807
Recruitment Status : Active, not recruiting
First Posted : October 8, 2020
Last Update Posted : April 4, 2022
Sponsor:
Information provided by (Responsible Party):
Istari Oncology, Inc.

Brief Summary:
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.

Condition or disease Intervention/treatment Phase
Melanoma Biological: Lerapolturev Biological: Anti-PD-1 Checkpoint Inhibitor Phase 2

Detailed Description:
This multi-center, open-label, randomized, Phase 2 will investigate the efficacy and safety of lerapolturev alone (Arm 1) or in combination with an anti-PD-1 inhibitor (Arm 2). Following a 6 participant safety run-in period, up to approximately 50 participants with cutaneous melanoma who previously failed anti-PD-1/L1-based therapy will be randomized 1:1 to receive either lerapolturev or lerapolturev plus an anti-PD-1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lerapolturev (Formerly Known as PVSRIPO) With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Actual Study Start Date : November 17, 2020
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Arm 1: Lerapolturev Only
Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 weeks thereafter.
Biological: Lerapolturev
Lerapolturev administered via direct lesion injection

Experimental: Arm 2: Lerapolturev and anti-PD-1
Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 or 4 weeks thereafter. Anti-PD-1 therapy given as per the anti-PD-1 approved package insert.
Biological: Lerapolturev
Lerapolturev administered via direct lesion injection

Biological: Anti-PD-1 Checkpoint Inhibitor
Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions




Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 24 months ]
    The proportion of patients achieving confirmed complete (CR) or partial response (PR), per RECIST 1.1 criteria

  2. Frequency and severity of treatment-emergent adverse events [ Time Frame: 24 months ]
    The frequency and severity of treatment-emergent adverse events (TEAE) via Common Terminology Criteria for Adverse Events (CTCAE, v5.0)

  3. Frequency and severity of adverse events of special interest (AESIs and AEs) [ Time Frame: 24 months ]
    Lerapolturev AESIs and anti-PD-1 immune related AEs (irAEs)

  4. Incidence of study treatment discontinuation due to adverse events (AEs) [ Time Frame: 24 months ]
    Study treatment discontinuation due to AEs

  5. Changes from baseline in the number of CD8+ tumor infiltrating lymphocytes (TILs) [ Time Frame: 24 months ]
    Changes from baseline in the number of CD8+ tumor infiltrating lymphocytes (TILs)

  6. Changes from baseline in PD-L1 expression [ Time Frame: 24 months ]
    Changes from baseline in PD-L1 expression


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 24 months ]
    Overall survival (OS): time from treatment group assignment until death from any cause.

  2. Duration of Response [ Time Frame: 24 months ]
    Duration of Response (DOR): time from confirmed objective response (CR or PR per RECIST 1.1) until unequivocal disease progression or death, whichever occurs first

  3. Disease Control Rate [ Time Frame: 24 months ]
    Disease control rate (DCR): the proportion of patients achieving confirmed CR, confirmed PR, or stable disease (SD) per RECIST1.1, as best response.

  4. DCR-6 months [ Time Frame: 24 months ]
    Disease control rate-6months (DCR-6mo): the proportion of patients achieving confirmed CR (any duration), confirmed PR (any duration) or SD (≥ 6 months) per RECIST 1.1 as best response.

  5. Durable Response Rate [ Time Frame: 24 months ]
    Durable Response Rate (DRR): the proportion of participants with confirmed CR or PR (per RECIST 1.1) lasting at least 6 months

  6. Progression-free survival (PFS) [ Time Frame: 24 months ]
    Progression-free survival (PFS): time (number of months) from treatment group assignment until date of documented radiologic disease progression per RECIST 1.1 or death due to any cause, whichever comes first


Other Outcome Measures:
  1. Lerapolturev mechanism of action and predictors of response to lerapolturev with or without anti-PD-1 in patients who have failed anti-PD1/L1 -based therapy [ Time Frame: 24 months ]
    • Assessment and identification of genetic, cytologic, histologic and/or other markers in tumor biopsies and PBMC samples that may correlate with response.
    • Assessment of changes over time in immune markers, including, but not limited to immune cell density, T cell receptor repertoire, and chemokine and/or cytokine profile in blood, samples, and/or tissue

  2. ORR based on iRECIST [ Time Frame: 24 months ]
    ORR based on iRECIST criteria

  3. DOR based on iRECIST [ Time Frame: 24 months ]
    DOR based on iRECIST criteria

  4. DRR based on iRECIST [ Time Frame: 24 months ]
    DRR based on iRECIST criteria

  5. DCR based on iRECIST [ Time Frame: 24 months ]
    DCR based on iRECIST criteria

  6. DCR-6mo based on iRECIST [ Time Frame: 24 months ]
    DCR-6mo based on iRECIST criteria

  7. ORR based on subgroup [ Time Frame: 24 months ]

    ORR in the following subgroups:

    • Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)
    • BRAF wild type and mutant
    • LDH levels at baseline
    • Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or >6 weeks)
    • Crossover to combination arm from lerapolturev monotherapy

  8. DOR based on subgroup [ Time Frame: 24 months ]

    DOR in the following subgroups:

    • Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)
    • BRAF wild type and mutant
    • LDH levels at baseline
    • Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or >6 weeks)
    • Crossover to combination arm from lerapolturev monotherapy

  9. DRR based on subgroup [ Time Frame: 24 months ]

    DRR in the following subgroups:

    • Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)
    • BRAF wild type and mutant
    • LDH levels at baseline
    • Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or >6 weeks)
    • Crossover to combination arm from lerapolturev monotherapy

  10. DCR based on subgroup [ Time Frame: 24 months ]

    DCR in the following subgroups:

    • Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)
    • BRAF wild type and mutant
    • LDH levels at baseline
    • Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or >6 weeks)
    • Crossover to combination arm from lerapolturev monotherapy

  11. DCR-6mo based on subgroup [ Time Frame: 24 months ]

    DCR-6mo in the following subgroups:

    • Acquired versus primary PD-1/L1 resistance as defined by Kluger, et al (2020)
    • BRAF wild type and mutant
    • LDH levels at baseline
    • Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or >6 weeks)
    • Crossover to combination arm from lerapolturev monotherapy

  12. OS based on subgroup [ Time Frame: 24 months ]

    OS in the following subgroups:

    • According to treatment arm and AJCC stage at baseline
    • Primary versus acquired resistance as defined by Kluger et al
    • BRAF wild type and mutant
    • LDH levels at baseline
    • Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or >6 weeks)
    • Crossover to combination arm from lerapolturev monotherapy

  13. PFS based on subgroup [ Time Frame: 24 months ]

    PFS in the following subgroups:

    • According to treatment arm and AJCC stage at baseline
    • Primary versus acquired resistance as defined by Kluger et al
    • BRAF wild type and mutant
    • LDH levels at baseline
    • Time since last dose of anti-PD1/L1 therapy prior to randomization (≤ or >6 weeks)
    • Crossover to combination arm from lerapolturev monotherapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ≥ 18 years of age
  2. Prior CDC-recommended vaccination series against PV, and has received a boost immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6 weeks, prior to Day 1

    a. NOTE: Patients who are unsure of their vaccination status must provide evidence of anti-PV immunity prior to enrollment, as applicable

  3. Has biopsy proven unresectable cutaneous melanoma and is willing to undergo tumor biopsy prior to the first dose of study drugs and at prespecified intervals during the study

    1. Patients with ocular, acral or mucosal melanoma are not eligible
    2. Patients with M1c or M1d disease are NOT eligble.
    3. Submission of an archival biopsy sample is allowed in lieu of the baseline tumor biopsy, provided the tissue is ≤4 months old and the participant received no intervening systemic/intratumoral anti-cancer therapy since the biopsy was acquired.
    4. Must have at least 1 lesion that is amenable to biopsy. The lesion must be safely accessible as determined by the investigator and should not be located at sites that require significant risk procedures to biopsy. Examples of sites considered to be of significant risk include but are not limited to the following: the brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel wall.
  4. Has ≥ 2 melanoma lesions that are accurately measurable by caliper or a radiological method according to RECIST 1.1 criteria

    1. One lesion must be injectable- defined as a visible or palpable cutaneous, subcutaneous, or nodal melanoma lesion ≥10 mm in longest diameter or multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥10 mm and where the minimum lesion size is ≥5 mm
    2. Note that visceral lesions (eg, liver, lung, retroperitoneal, subpleural lesions) are not considered injectable for the purposes of this trial.
  5. Has had confirmed progression of disease (PD) while receiving at least 6 weeks (> 1 dose) of an FDA-approved anti-PD-1/L1 therapy (as monotherapy or in combination) for the treatment of melanoma. Note the following details:

    1. Initial PD as defined by RECIST v1.1
    2. Confirmation of PD per iRECIST must occur by repeat assessment ≥ 4 weeks from initial evidence of PD, in the absence of rapid clinical progression.
    3. Those who discontinue anti-PD-1/L1 therapy after at least 6 weeks (> 1 dose) and have confirmed PD per iRECIST within 12 weeks of their last anti-PD-1/L1 dose are also eligible, provided the anti-PD-1/L1 was not stopped due to toxicity requiring permanent discontinuation
    4. Those treated with anti-PD-1/L1 in the adjuvant setting and who have biopsy-confirmed progression either while receiving anti-PD-1/L1-based therapy or ≤ 12 weeks after their last dose of anti-PD-1/L1 therapy are allowed NOTE: Adjuvant is defined as therapy received after surgical resection of disease such that the patient has no evidence of disease when the anti-PD-1/L1 therapy is initiated. Patients with known BRAF mutation must have also failed or refused to receive BRAF-targeted therapy (alone or in combination with MEK inhibitor) to be eligible.
  6. Eastern Cooperative Oncology Group (ECOG) status of 0-1
  7. Serum lactate dehydrogenase (LDH) levels ≤ 3 x upper limit of normal (ULN)
  8. Adequate bone marrow, liver and renal function as assessed by the following:

    1. Hemoglobin ≥ 9.0 g/dl, patients may be transfused
    2. Lymphocyte count ≥ 0.5 x 10^9/L (500 µL)
    3. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500 µL)
    4. Platelet count ≥ 100 x 10^9/L (100,000 µL) without transfusion
    5. AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), with the following exceptions: Patients with documented liver metastases: AST and ALT ≤ 5 x ULN; Patients with documented liver or bone metastases: ALP ≤ 5 x ULN
    6. Serum bilirubin ≤ 1.5 x ULN with the following exception: Patients with known Gilbert disease: serum bilirubin level ≤ 3 x ULN
    7. Measured or calculated (per institutional standards) creatinine clearance ≥ 30 ml/min (GRF can also be used in place of creatinine clearance)
    8. For patients not receiving therapeutic anticoagulation: INR, PT, PTT (or aPTT) ≤ 1.5 x ULN
  9. Life expectancy of >12 weeks
  10. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for the study, and is willing/able to participate in the study

Exclusion Criteria:

  1. Has biopsy-proven ocular, acral or mucosal melanoma
  2. Has M1c or M1d disease
  3. No more than one prior systemic anti-cancer regimen (monotherapy or combination) for management of melanoma. Additional details noted below:

    1. Adjuvant anti-cancer therapy administered ≥ 6 months prior to the first injection of lerapolturev does NOT count as a line of treatment.
    2. Patients with BRAF mutant melanoma may enroll if they have received ≤ 2 prior lines of systemic anti-cancer therapy only if one of those lines of therapy was a BRAF-targeted regimen (alone or in combination with MEK inhibitor).
    3. A line of therapy is defined as a regimen in which at least 2 doses of systemic anti-cancer therapy (monotherapy or combination) was administered, and the regimen was discontinued because of progressive disease
  4. Uncontrolled tumor-related pain. Participants requiring pain medication must be on a stable regimen at study entry.

    1. Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastases causing nerve impingement) should treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period
    2. Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment
  5. Grade ≥2 pleural effusion, pericardial effusion, or ascites
  6. Active or history of autoimmune disease or immune deficiency within previous 2 years, with the following exceptions:

    1. History of autoimmune-related endocrinopathy (e.g. adrenal insufficiency, hypothyroidism, Type 1 diabetes mellitus, etc.) that is managed by hormone replacement therapy (e.g. hydrocortisone, thyroid hormone, insulin, etc.)
    2. Eczema, psoriasis, or lichen simplex chronicus with dermatologic manifestations only (eg, patients with psoriatic arthritis are excluded), provided all of the following conditions are met:

    i. Rash must cover <10% of body surface area

    ii. Disease is well-controlled at baseline and requires only low-potency topical corticosteroids

    iii. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within 12 months of Day 1

  7. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan

    a. History of radiation pneumonitis in the radiation field (fibrosis) is allowed.

  8. History of a positive HIV RNA test (HIV 1 or 2 RNA by PCR)
  9. Known active hepatitis B virus (HBV) infection (chronic or acute)

    a. NOTE: Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are allowed.

  10. Known active hepatitis C virus (HCV) infection

    a. NOTE: History of a positive HCV antibody test, but negative HCV RNA test is allowed.

  11. Active tuberculosis
  12. Significant cardiovascular disease, such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months of Day 1, unstable arrhythmia, or unstable angina
  13. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 elimination half-lives- whichever is shorter, prior to treatment, or has not recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy are eligible

    1. Note: Anti-PD-1/L1 within 4 weeks prior to Day 1 is allowed
    2. If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
  14. History of other malignancy within 2 years prior to Day 1, with the exception of those with a negligible risk of metastasis or death (e.g., resected cutaneous basal cell carcinoma, or other cancers with 5-year OS of >90%)
  15. Severe infection within 4 weeks prior to Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

    a. Prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are allowed.

  16. Prior allogeneic stem cell or solid organ transplantation
  17. Treatment with a live, attenuated vaccine within 4 weeks prior to Day 1
  18. Treatment with systemic immunosuppressive medication within 4 weeks prior to Day 1, with the following exceptions:

    1. Participants who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible
    2. Patients receiving mineralocorticoids (e.g., fludrocortisone), or systemic prednisone equivalent corticosteroid doses of <10mg per day are eligible for the study
  19. Known hypersensitivity to pembrolizumab, nivolumab, or any of the respective excipients
  20. Requires therapeutic anticoagulation and cannot discontinue anticoagulation safely during the day prior, day of, and day after each lerapolturev injection

    a. NOTE: Participants receiving anticoagulation with warfarin at the time of study entry are allowed if they can be transitioned to an alternative anticoagulant (eg, low molecular weight heparin or direct oral anticoagulants) prior to the first dose of lerapolturev. Anyone transitioned from warfarin to an oral anticoagulant prior to the first dose of lerapolturev should have an INR <1.5x upper limit of normal in order to participate. Antiplatelet agents (eg, aspirin, clopidogrel, etc.) are not considered anticoagulants for the purposes of this study (ie, are allowed)

  21. A pregnant or nursing female, or women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception starting from signed ICF through 150 days after last anti-PD-1 dose
  22. History of human serum albumin allergy
  23. History of neurological complications due to polio virus infection
  24. History of agammaglobulinemia
  25. Concurrent participation in a separate interventional clinical trial during this study.
  26. Any underlying medical condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromises the participant's well-being) or that could prevent, limit, or confound protocol-specified assessments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04577807


Locations
Show Show 20 study locations
Sponsors and Collaborators
Istari Oncology, Inc.
Layout table for additonal information
Responsible Party: Istari Oncology, Inc.
ClinicalTrials.gov Identifier: NCT04577807    
Other Study ID Numbers: LUMINOS-102
First Posted: October 8, 2020    Key Record Dates
Last Update Posted: April 4, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas